Subscribe To
NLTX / Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
Content Topics
Neoleukin
Therapeutics
Present
Canaccord
Genuity
Horizons
Oncology
Conference
Stock
NLTX
NLTX News
By GuruFocus
July 27, 2023
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Fi more_horizontal
By Seeking Alpha
April 19, 2023
Neoleukin Therapeutics: Strategic Review Play
Neoleukin Therapeutics: Strategic Review Play more_horizontal
By Zacks Investment Research
March 10, 2023
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of more_horizontal
By GeekWire
March 9, 2023
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statemen more_horizontal
By Seeking Alpha
August 10, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor R more_horizontal
By GlobeNewsWire
April 7, 2022
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophist more_horizontal
By Seeking Alpha
March 1, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 1, 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript more_horizontal